Cancer- undergrupperne i undersøgelsen skal bestå af de patienter, der er i behandling med Casodex (bicalutamid) og dem, hvis behandling består i GnRH - analoger, orkiektomi eller anden hormonbehandling.
Further, the study will include prostate cancer subgroups to include those on Casodex (bicalutamide), and those treated with luteinizing hormone-releasing hormone (LHRH) analogues, orchidectomy, and other hormonal therapies.